Next-generation nanoparticles for cancer and autoimmune therapy
<p>Immune modulation is a critical therapeutic approach for cancer and autoimmune diseases, aiming to balance immune activation and suppression within specific disease environments. Next-generation nanoparticles (NPs) offer a promising method for precisely delivering cytokines and other immune...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , |
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <p>Immune modulation is a critical therapeutic approach for cancer and autoimmune diseases, aiming to balance immune activation and suppression within specific disease environments. Next-generation nanoparticles (NPs) offer a promising method for precisely delivering cytokines and other immune modulators, addressing challenges such as systemic toxicity and limited specificity. This review explores the dual function of NPs in modulating pro- and anti-inflammatory responses, enhancing immune detection and tumor elimination in cancer, while promoting immune tolerance in autoimmune diseases. Advanced NP design strategies are highlighted, including stimuli-responsive systems tailored for the tumor microenvironment (TME) and inflamed tissues, as well as co-delivery platforms that combine cytokines with immune checkpoint inhibitors (ICIs). Additionally, dual-function NPs designed to target multiple immune pathways simultaneously are examined, offering innovative solutions for complex diseases. Despite ongoing challenges related to compatibility, safety, and scalability, the integration of nanotechnology with immune modulation presents significant potential to transform therapeutic outcomes. Future research should focus on overcoming these limitations to enhance clinical applications. By leveraging the precision and adaptability of next-generation NPs, a new frontier in immune therapy is emerging, offering more effective and targeted treatments for cancer and autoimmune diseases.</p><h2>Other Information</h2> <p> Published in: Biochemical Pharmacology<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.bcp.2025.117298" target="_blank">https://dx.doi.org/10.1016/j.bcp.2025.117298</a></p> |
|---|